Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach.

Creative Commons License

Özen S., Sag E., Ben-Chetrit E., Gattorno M., Gül A., Hashkes P. J., ...Daha Fazla

Rheumatology (Oxford, England), cilt.60, ss.3799-3808, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1093/rheumatology/keaa863
  • Dergi Adı: Rheumatology (Oxford, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.3799-3808
  • Anahtar Kelimeler: inflammation, autoinflammatory conditions, quality of life care, outcome measures, DMARD, CHILDREN, RECOMMENDATIONS, MANAGEMENT, FMF
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives. Colchicine is the main treatment for FMF. Although a number of individuals with FMF are intolerant/resistant to colchicine, there is no standard definition of colchicine resistance/intolerance. We developed a set of evidence-based core statements defining colchicine resistance/intolerance in patients with FMF that may serve as a guide for clinicians and health authorities.